Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vermersch

Showing results (151-160 of 250) with videos related to

Pageof 25
Sort By:
Multiple Sclerosis and Related Disorders|January 6, 2020
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosisJohn Foley, Cynthia Carrillo-Infante, Jonathan Smith, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 18, 2012
Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective studyJean-Baptiste Chanson, Andoni Echaniz-Laguna, Frédéric Blanc, et al.
Alzheimer'S Research & Therapy|February 28, 2023
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trialBruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, et al.
Multiple Sclerosis and Related Disorders|June 14, 2019
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study<sup>★★</sup>Aaron E Miller, Patrick Vermersch, Ludwig Kappos, et al.
Journal of Neurology|February 5, 2011
Cancer and multiple sclerosis in the era of disease-modifying treatmentsChristine Lebrun, Patrick Vermersch, David Brassat, et al.
Archives of Neurology|March 14, 2012
Long-term follow-up of acute partial transverse myelitisBertrand Bourre, Hélène Zéphir, Jean-Claude Ongagna, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2013
JC-virus seroconversion in multiple sclerosis patients receiving natalizumabOlivier Outteryck, Hélène Zéphir, Julia Salleron, et al.
Archives of Neurology|January 16, 2008
Neuromyelitis optica and non organ-specific autoimmunitySean J Pittock, Vanda A Lennon, Jerome de Seze, et al.
The New England Journal of Medicine|February 14, 2024
Inhibition of CD40L with Frexalimab in Multiple SclerosisPatrick Vermersch, Cristina Granziera, Yang Mao-Draayer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2021
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis opticaEdouard Januel, Jérôme De Seze, Patrick Vermersch, et al.
Pageof 25

Showing results (151-160 of 250) with videos related to

Sort By:
Pageof 25
Multiple Sclerosis and Related Disorders|January 6, 2020
The 5-year Tysabri global observational program in safety (TYGRIS) study confirms the long-term safety profile of natalizumab treatment in multiple sclerosisJohn Foley, Cynthia Carrillo-Infante, Jonathan Smith, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|December 18, 2012
Central nervous system abnormalities in patients with PMP22 gene mutations: a prospective studyJean-Baptiste Chanson, Andoni Echaniz-Laguna, Frédéric Blanc, et al.
Alzheimer'S Research & Therapy|February 28, 2023
Masitinib for mild-to-moderate Alzheimer's disease: results from a randomized, placebo-controlled, phase 3, clinical trialBruno Dubois, Jesús López-Arrieta, Stanley Lipschitz, et al.
Multiple Sclerosis and Related Disorders|June 14, 2019
Long-term outcomes with teriflunomide in patients with clinically isolated syndrome: Results of the TOPIC extension study<sup>★★</sup>Aaron E Miller, Patrick Vermersch, Ludwig Kappos, et al.
Journal of Neurology|February 5, 2011
Cancer and multiple sclerosis in the era of disease-modifying treatmentsChristine Lebrun, Patrick Vermersch, David Brassat, et al.
Archives of Neurology|March 14, 2012
Long-term follow-up of acute partial transverse myelitisBertrand Bourre, Hélène Zéphir, Jean-Claude Ongagna, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 28, 2013
JC-virus seroconversion in multiple sclerosis patients receiving natalizumabOlivier Outteryck, Hélène Zéphir, Julia Salleron, et al.
Archives of Neurology|January 16, 2008
Neuromyelitis optica and non organ-specific autoimmunitySean J Pittock, Vanda A Lennon, Jerome de Seze, et al.
The New England Journal of Medicine|February 14, 2024
Inhibition of CD40L with Frexalimab in Multiple SclerosisPatrick Vermersch, Cristina Granziera, Yang Mao-Draayer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|December 21, 2021
Post-vaccine COVID-19 in patients with multiple sclerosis or neuromyelitis opticaEdouard Januel, Jérôme De Seze, Patrick Vermersch, et al.
Pageof 25